The following articles appeared in the print edition of HemOnc Today.
Table of Contents
-
Use of erythropoiesis-stimulating agents: an ongoing controversy
-
-
Are restrictions on ESA use justified?
-
BRCA mutations in women with ovarian cancer correlated with longer
survival
-
CDC report: Nearly 20% of Americans cannot afford needed health care
-
Congress delays 10.1% cut to Medicare physician payments
-
Congress increases scrutiny of Medicare Recovery Audit Contractors
Anthony H. Choe, JD, MPH
-
Lung cancer: the invisible disease
Toby C. Campbell, MD, MSCI
-
Metastatic colorectal cancer: timing and selecting best management options
Wajeeha Razaq, MD
-
Progress in the treatment of PNH: decisions, decisions, decisions
Wendell F. Rosse, MD
-
-
Bloodletting: an early treatment used by barbers, surgeons
-
Imaging of human reporter genes has translational applications
Ronald Blasberg, MD
-
Factor V Leiden and prothrombin mutation linked to venous thrombosis
-
Lenalidomide decreases transfusion dependence in MDS not related to 5q deletion
-
Rivaroxaban efficacious after orthopedic surgery
-
Manpower needed in Eritrea
-
End-of-life care: when chemotherapy may not be the best option
Thomas J. Smith, MD; Keith M. Swetz, MD